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Abstract  
Colorectal carcinoma (CRC) is one of the leading causes of cancer related deaths; in Egypt it constitutes 6.5% of all cancers. 
Previous studies have shown conflicting results on clinicohistopathological features and survival of patients with colorectal 
mucinous (MA) and non-mucinous adenocarcinoma (NMA). To the best of our knowledge, this study is the first to investigate 
these features in Egypt. In this work, we studied tumor tissue specimens from 150 patients with colorectal MA and NMA who 
underwent radical surgery from Jan 2007 to Jan 2012 at Gastroenterology Centre, Mansoura University, Egypt. Their 
clinicohistopathological parameters and survival were analyzed using established statistical methodologies. Incidence of MA and 
its subtypes was much higher in Egypt than worldwide incidence. MA was significantly associated with younger age, more depth 
of invasion, lymph node metastasis, less microscopic abscess formation and less peri-tumoral lymphocytic response (Crohn-like 
response) than NMA. Both groups were not significantly different "among others" in other clinicopathological parameters 
including lymphovascular and perineural invasion, association with adenoma and schistosomiasis. Multivariate analyses for 
disease free and overall survival revealed that mucinous histology is an independent prognostic factor. Among several factors, only 
distant metastasis and presentation with recurrent disease were independent prognostic factors within MA patients. In conclusion, 
MA represents a distinct clinicopathological entity with worse survival than NMA. Distant metastasis and presentation with 
recurrent disease are independent prognostic factors. Further molecular investigations considering genetic features of MA will lead 
to drug development and better management. 
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Introduction 
Colorectal carcinoma (CRC) is a major cause of 
morbidity and mortality throughout the world. It is the 
third most common cancer worldwide and the fourth 
most common cause of death [1]. It constitutes 9.5% of 
all cancers worldwide [2] whereas; in Egypt it 
contributes 6.5% of all cancers [3].  
Mucinous adenocarcinoma (MA), a morphologic 
subtype of CRC, has more than 50% of the tumor 
composed of mucin, either extracellular with mucin lakes 
(colloid carcinoma) or intracellular where more than 
50% of the tumor consists of signet ring cells (signet ring 
cell adenocarcinoma) [4]. 
Both colloid and signet ring adenocarcinomas are 
relatively rare, and this contributes to the difficulty of 
examining their clinicopathological features as well as 
survival outcomes [5]. In general, MA accounts for 
5%-15% of CRC [6, 7] and signet ring cell tumors 
account for approximately 1%
 
[8]. 
The importance of these distinct histological 
appearances lies in the observed differences between MA 
and NMA with regard to clinicopathological 
characteristics, distinct genetic profiles, and pathogenic 
pathways [9]. 
In this study, we aimed to clarify the 
clinicohistopathological characteristics and survival of 
colorectal MA and NMA in the Egyptian population.  
Material and methods 
Samples:  
This retrospective study was carried out in surgical 
pathology lab at Gastroenterology Center, Mansoura, 
Egypt.  Files of all resected CRC cases were revised 
during the period from 2007 to 2011 (341 cases). MA 
cases were selected and revised (75 cases). Another 75 
cases of NMA were chosen randomly for comparison 
from the same period. 
Clinical parameters and histopathological evaluation:  
All clinicopathological data of the 150 cases were 
revised with re-examination of all their slides to evaluate 
histological criteria. This includes: age, gender, location, 
size, shape, multiplicity, histological type, percent of the 
subtype, grade, depth of invasion (T), tumor margins, 
lymphovascular invasion, perineural invasion, peri- and 
intra-tumoral lymphocytic infiltration, extent of 
neutrophilic infiltrate, nearby and distant mucosa, 
whether the tumor was on top of adenoma or not, 
number of LN metastases (N), distant metastasis (M), 
TNM staging, state of surgical cut margins, associated 
ulcerative colitis, associated schistosomiasis, exact site of 
the ova and any other finding. 
Histological types and stages were classified by 
pathologists using the World Health Organization 
(WHO) criteria [4].  
Survival and Statistical analysis 
Data were analyzed, applying SPSS, version 16.0 for 
Windows (SPSS Inc, IBM, and Chicago, Illinois). χ2 
(Chi-square) test was used to test significant differences 
between MA and NMA groups. Survival data were 
analyzed using Kaplan-Meier test. A comparison of 
survival curves was carried out using the log-rank test. 
For multivariate analysis, Cox proportional hazard 
models were performed. A 2-tailed P ≤ 0.05 was 
considered significant in all tests. 
Results 
Demographics 
In total, 75 cases of MA out of 341 cases of CRC 
(22%) were received at surgical pathology lab at 
Gastroenterology Center, Mansoura, Egypt, during the 
period from 2007 to 2011. They included 56 cases of 
colloid adenocarcinoma (16.7% of all cases) and 19 
cases of signet ring adenocarcinoma (5.6% of all cases). 
Age range at presentation for NMA was 27 to 78 years 
(mean, 54.9 years) and 20 to 80 years (mean, 50.5 years) 
for MA. Patients with MA were statistically younger than 
those with NMA (P=0.017) (table 1). 
The participants were 93 men and 57 women, with no 
significantly detected difference in gender between both 
groups (P=0.614) (table 1). 
Tumor characteristics 
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In this study, 150 CRC cases were analyzed. Seventy 
five NMA included 47 cases of ordinary 
adenocarcinoma and 28 cases of adenocarcinoma with 
mucinous component <50% of the tumor. The other 75 
cases of MA cases included 56 cases of colloid 
adenocarcinoma and 19 cases of signet ring cell 
carcinoma. 
The clinicopathological and histological features of 75 
cases of MA and 75 cases of NMA are listed in Tables 
1&2.  
Regarding clinicopathological features, MA and 
NMA groups were not significantly different in tumor 
size, location, gross picture, multiplicity, surgical cut 
margins and pathological TNM staging (Table 1). 
Ninety-two percent of MA cases showed invasion of 
the tumor beyond the muscularis mucosa, which was 
significantly higher than NMA (P=0.008). Less than 
50% of NMA cases and more than 60% of MA cases 
showed LN metastasis at the time of presentation; MA 
was significantly associated with more frequency of LN 
metastasis (P=0.008) (Table 1). 
Regarding histological features, MA and NMA were 
not significantly different in the frequency of 
lymphovascular invasion, perineural invasion, associated 
adenoma, associated schistosomiasis, configuration of 
tumor margins and intra-tumoral lymphocytic infiltration 
(Table 2). 
However, about 70% of NMAs showed massive 
debris and leucocytes infiltration (mainly neutrophils) at 
the surface and invasive tumor margin “Microscopic 
abscess formation”, which was significantly higher than 
MA (P<0.001) (Table 2). 
Additionally, about 80% of mucinous CRC cases 
showed negative peri-tumoral lymphocytic response 
“Crohn-like response”, which was significantly lower 
than NMA (P=0.017) (Table 2)       
Survival  
To clarify the prognostic impact of mucinous 
histology on CRC, univariate and multivariate analyses 
were carried out. The 3 years disease free survival (DFS) 
for patients with MA was 49.3% compared to 62.2% in 
NMA patients. The median DFS was significantly lower 
for patients with MA compared to patients with NMA, 
median 17 months (95% CI 13.8-20.2) versus 58 months 
(95% CI 47-69) respectively; (p < 0.001) (Figure 1A). 
Multivariate analysis demonstrated that MA histology is 
independent negative predictor of DFS (HR: 2.2, 95% CI 
1.2 - 4.04, P= 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 (a): DFS (months, log-rank test) in patients with colorectal carcinoma related to mucinous versus non-mucinous 
histology (P < 0.001). (b): OS (months, log-rank test) in patients with colorectal carcinoma related to mucinous versus non-mucinous 
histology (P < 0.001). 
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Table 1 Clinicopathological features of 150 cases of mucinous and non-mucinous CRC 
 
P 
value 
Chi-square (χ2) 
Mucinous  Non-Mucinous  
 
No. (%) No. (%) 
 
0.017* 
 
5.720 
 
22 (29.3%) 
53 (70.7%) 
 
10 (13.3%) 
65 (86.7%) 
Age (y) 
- < 40 
- ≥ 40 
 
0.614 
 
0.255 
 
45 (60.0%) 
30 (40.0%) 
 
48 (64.0%) 
27 (36.0%) 
Gender 
- Male 
- female 
 
0.101 
 
2.690 
 
36 (48.0%) 
39 (52.0%) 
 
46 (61.3%) 
29 (38.7%) 
Tumor size 
- < 6 
- ≥ 6 
 
0.829 
 
0.887 
 
23 (30.7%) 
6 (8.0%) 
41 (54.7%) 
5 (6.7%) 
 
18 (24.0%) 
6 (8.0%) 
45 (60.0%) 
6 (8.0%) 
Location 
- Right 
- Left 
- Recto-sigmoid 
- Transverse 
 
0.330 
 
2.218 
 
27 (36.0%) 
27 (36.0%) 
21 (28.0%) 
 
34 (45.3%) 
19 (25.3%) 
22 (29.3%) 
Gross picture 
- Fungating 
- Ulcerating 
- Annular 
 
0.290 
 
1.119 
 
69 (92.0%) 
6 (8.0%) 
 
65 (86.7%) 
10 (13.3%) 
Multiplicity 
- Negative 
- Positive 
 
 
0.467 
 
 
0.28 
 
 
70 (93.3%) 
5 (6.7%) 
 
 
72 (96.0%) 
3 (4.0%) 
Surgical cut margins 
- Free 
- Infiltrated 
 
0.008* 
 
7.143 
 
6 (8.0%) 
69 (92.0%) 
 
18 (24.0%) 
57 (76.0%) 
Depth of invasion 
- T1/T2 
- T3/T4 
 
0.008* 
 
9.729 
 
27 (36.0%) 
19 (25.3%) 
29 (38.7%) 
 
38 (50.7%) 
25 (33.3%) 
12 (16.0%) 
LN 
- N0 
- N1 
- N2 
 
0.172 
 
1.862 
 
4 (5.3%) 
71 (94.7%) 
 
1 (1.3%) 
74 (98.7%) 
Metastasis 
- M1 
- Mx 
 
0.099 
 
2.725 
 
27 (36.0%) 
48 (64.0%) 
 
37 (49.3%) 
38 (50.7%) 
TNM stage 
- I /II 
- III /IV 
* P ≤ 0.05 is significant. 
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Table 2 Histological features of 150 cases of mucinous and non-mucinous CR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* P ≤ 0.05 is significant. 
 
Patients with MA had significantly lower 5 years 
overall survival (OS) (20%) than those with NMA 
(50.7%), the median OS for patients with MA and NMA 
was 22 months (95% CI 19.5 - 24.5) and 61 months 
(95% CI 50–72), respectively; (P = <0.001) (Figure 1B). 
Furthermore, MA was noted to be independent 
prognostic factor for OS in multivariate analysis (HR: 
2.38, 95% CI 1.3 - 4.4, P = 0.006). 
Within the group of MA, a univariate analysis was 
done to test parameters with impact on DFS and/or OS 
using Kaplan–Meier analysis. It revealed that T4 disease, 
positive LN, lymphovascular emboli, perineural invasion, 
recurrent disease as well as distant metastasis were 
significant negative prognostic variables. For the 
remaining clinicopathological and histological factors, 
there were no significant prognostic values (data not 
P value 
Chi-square 
(χ2) 
Mucinous Non Mucinous  
 No. (%) No. (%) 
 
0.232 
 
1.430 
 
23 (30.7%)    
52 (69.3%) 
 
30 (40.0%) 
45 (60.0%) 
Lymphovascular emboli 
-Negative 
-Positive 
 
0.294 
 
1.103 
 
48 (64.0%) 
27 (36.0%) 
 
54 (72.0%) 
21 (28.0%) 
Perineural invasion 
-Negative 
-Positive 
 
0.743 
 
0.107 
 
41 (54.7%) 
34 (45.3%) 
 
39 (52.0%) 
36 (48.0%) 
Associated adenoma 
-Negative 
-Positive 
 
 
0.497 
 
 
0.462 
 
 
62 (82.7%) 
13 (17.3%) 
 
 
65 (86.7%) 
10 (13.3%) 
Associated 
schistosomiasis 
-Negative 
-Positive 
 
0.772 
 
0.084 
 
69 (92.0%) 
6 (8.0%) 
 
68 (90.7%)   
7 (9.3%) 
Tumor margins 
-Budding 
-Pushing 
 
 
<0.001* 
 
 
16.679 
 
 
49 (65.3%) 
26 (34.7%) 
 
 
24 (32%) 
51 (68%) 
Microscopic abscess 
formation 
-Negative 
-Positive 
 
 
 
0.017* 
 
 
 
5.672 
 
 
 
61 (81.3%) 
14 (18.7%) 
 
 
 
48 (64.0%)   
27 (36.0%) 
Peri-tumoral lymphocytic 
response (Crohn-like 
response) 
-Negative 
-Positive 
 
 
0.246 
 
 
1.349 
 
 
73 (97.3%) 
2 (2.7%) 
 
 
70 (93.3%)   
5 (6.7%) 
Intra-tumoral 
lymphocytic response  
-Negative 
-Positive 
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shown). However, by applying multivariate Cox 
regression analysis to test the prognostic yield of these 
parameters, no significant independent negative 
predictors for DFS (Table 3), both distant metastasis and 
recurrent disease proved to be independent significant 
prognostic factors regarding OS (Table 4). 
 
Table 3 Multivariate analysis of prognostic factors by the Cox’s proportional hazards regression models of patients with 
mucinous adenocarcinoma with respect to disease-free survival 
 
 Risk ratio CI P-value 
T4 disease 2.2 0.63 - 7.69 0.22 
Positive LN 1.33 0.86 - 2.06 0.19 
Lymphovascular emboli 1.39 0.6 - 3.23 0.44 
Perineural invasion 1.22 0.7 - 2.13 0.48 
Presentation by recurrent disease 1.33 0.32 - 5.51 0.69 
 
Table 4 Multivariate analysis of prognostic factors by the Cox’s proportional hazards regression models of patients with 
mucinous adenocarcinoma with respect to overall survival 
 
 Risk ratio CI P-value 
T4 disease 1.12 0.41 - 3.08 0.83 
Positive LN 1.32 0.86 - 2 0.20 
Lymphovascular emboli 1.45 0.63 - 3.32 0.38 
Perineural invasion 1.28 0.75 - 2.2 0.37 
Presentation by recurrent disease 4.08 1.27 - 13.09 0.018* 
Distant metastasis 0.02 0.005 - 0.111 < 0.001* 
* P ≤ 0.05 is significant. 
 
Discussion 
  MA is a commonly studied histological subtype 
of CRC. However, the prognostic value of mucinous 
histology remains controversial. To the best of our 
knowledge, this is the first study of 
clinicohistopathological features and survival of MA and 
NMA in Egypt.  
In our study, the incidence of MA in general in Egypt 
was nearly double that of worldwide incidence. 
Especially, incidence of signet ring carcinoma in Egypt 
was 5 times higher than worldwide incidence. These 
findings suggest that genetic factors may be play an 
important role in the development of this subtype in our 
country, and further studies are needed to explore these 
genetic factors. 
The importance of this distinct subtype lies in the 
observed differences between MA and NMA with regard 
to clinicopathological characteristics, distinct genetic 
profiles, and pathogenic pathways [9].  
Consistent with our study, previous reports showed 
that MA group had worse clinical factors when 
compared to NMA group, including younger age at 
presentation [6, 7, 9-11].This finding shows that the 
younger the age at presentation, the more malignant the 
behavior of the tumor and the shorter the expected 
survival [12]. Surprizingly, Yamaguchi et al. [13] 
reported no difference in age between both groups 
although they investegated about 4300 cases of CRC! 
MA was more frequent in men than in women in 
some reports [14, 15], whereas our data are in line with 
more previous studies [9, 12, 13], that similarly 
identified no significant diffrence in gender between both 
groups. 
Several studies had also observed larger tumor size in 
MA than NMA [6, 9, 12, 13, 16-18]. Consistent with 
Chiang et al., we didn’t find this relation. 
Regarding location of the tumor, several studies had 
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observed that MA occured more frequently within the 
right hemicolon [6, 13, 17, 20-23]. However, consistent 
with Mekenkamp et al. [9], MA in our study occured 
also more frequently within the right hemicolon and 
rectosigmoid, but this was not statistically significant. 
To the best of our knowledge, this is the first study to 
investigate gross appearance of the tumor (either 
fungating, ulcerating or annular), multiplicity and state of 
surgical cut margins either infiltrated or not, within MA 
and NMA groups. Both groups showed no statistically 
significant difference in these parameters. 
In this study, our data confirmed that of most studies 
about deeper invasion of MA than NMA [6, 7, 9-11, 13]. 
However, some studies didn’t detect a difference 
between both groups [17].  
Similarly, we reported higher frequncy of LN 
metastasis with MA as previous studies [6, 7, 10-13, 20, 
22].  On the other hand, other studies didn’t [9, 17].  
Because of previous conflicting results regarding 
depth of invasion and LN metastasis, the influence of 
mucinous histology on TNM staging of CRC is still in 
dispute. Many studies reported higher stage at time of 
diagnosis for MA than NMA
 
[13, 16, 19, and 20]. 
However, other studies showed that MA was not 
significantly different from NMA in staging [16, 24, and 
25]. In our study, although MA showed significantly 
more depth of invasion and more LN metastases than 
NMA, TNM staging was not significantly different 
between both groups. 
These wide variations in clinicopathological features 
reported by many studies on MA and NMA can be 
attributed to large variations of the number of cases of 
each study, difference in races, genetic alterations, and 
wide heterogeneity of sampling criteria of the cases in 
addition to limitations inherent to retrospective analyses. 
Histological criteria of MA and NMA were not 
extensively examined as their clinicopathological 
counterparts. This may be attributed to the nature of most 
previous studies that were dependent only on registries of 
their centers and focusing on survival data only. In this 
study, MA and NMA groups were not significantly 
different in lymphovascular and perineural invasion as 
reported by Langner et al. [17]. In our study, the two 
groups were not significantly different in association 
with adenomas.  
Although our locality is endemic for schistosomiasis, 
no significant association with either group was detected 
in present study. Contrasting to this result, a previous 
study by Madbouly et al. [26] had shown that 
schistosoma mansoni-associated CRCs have distinctive 
pathological features including high percentage of 
multicentric tumors and mucinous type. In this study, 
CRC associated with bilharzial lesions was 15.3 % with 
a frequency slightly lower than the frequency reported by 
EL-Bolkainy et al. [27]. 
For MA, few studies examined the histological 
features at the tumor invasive front and their prognostic 
significance. Kakar et al. [28] classified MA into those 
with pushing and infiltrative advancing fronts, and 
showed that infiltrative growth was not related 
significantly to a poorer prognosis. On the other hand, 
Yamaguchi et al. [13] identified infiltrative growth 
pattern as an independent prognostic factor in MA. 
Langner et al. [17] demonstrated a significant 
association between mucinous histology and expansive 
(pushing) tumor border, in relation to infiltrative 
(budding) margin in NMA. However, we didn’t find 
these relations. About 90% of MA and NMA groups in 
our study showed infiltrative rather than bushing 
margins. 
Microscopic abscess formation was defined as the 
presence of debris and leucocytes (mainly neutrophils) at 
the invasive tumor margin, and was considered to be 
associated with more favourable outcome in rectal 
cancers [29]. Yamaguchi et al. [13]
 
reported that MA 
was significantly associated with negative microscopic 
abscess formation. Our data confirmed these findings; 
about 65% of MA cases in our study were associated 
with negative microscopic abscess formation, which was 
significantly different from NMA that was associated 
with more microscopic abscess formation. In addition, 
we detected this abcess formation at the surface of the 
tumor as well as its advancing edge. However there is 
accumulating evidence for an important role of 
inflammation in tumor progression, it seems that MA 
does not depend on these roles for invasion; rather it 
invades by dissecting tissue planes with prevention of 
immunological recognition of tumor cells by interfering 
with inflammatory responses [19, 30]. Our data are also 
in line with Yamaguchi et al. [13] who similarly 
identified significantly lower peri-tumoral lymphocytic 
(Crohn-like) infiltrate in MA than NMA. More than 80% 
of MA cases in this study were associated with negative 
Crohn-like response. This finding further emphasises 
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that MAs are less immunogenic than NMAs, and 
supports the concept of prevention of immunological 
recognition of tumor cells either by interfering with 
inflammatory responses or by wrapping the tumor cells 
by mucin. In contrast, there was no significant difference 
between MA and NMA groups regarding intra-tumoral 
lymphocytic infiltrate. 
The prognostic value of MA is still highly 
controversial. Our data confirmed those of most studies 
reported that MA was associated with poor prognosis [6, 
15, 16, 21, 23], while others found no correlation 
between this histological subtype and clinical outcome
 
[31- 34]. 
Moreover, the reasons beyond this poor prognosis of 
MA are still also in dispute. Some studies revealed that 
advanced stage at presentation was the main factor [13, 
16, 19, and 20]. Consistent with Kang et al. [8] and 
Yamaguchi et al. [13], we didn’t found staging to be an 
independent prognostic factor. Conversely, in agreement 
with Kang et al. [8], we confirmed that distant metastasis 
is an independent prognostic factor. Moreover, 
presentation with recurrent disease is another 
independent prognostic factor in our study. However, T4 
tumors, positive LN metastases, lymphovascular emboli 
and perineural invasion were associated with poor 
survival in univariate but not multivariate analyses in the 
present study. 
In conclusion, MA represents a distinct 
clinicopathological entity with worse survival than NMA. 
Distant metastasis and presentation with recurrent 
disease are independent prognostic factors. Further 
molecular studies considering genetic features of MA 
will lead to tailored drug development and better 
management. 
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